-
821
Cytopathological characteristics for provoked lesions of squamous epithelia of digestive system in animal models
Published 2022-03-01Subjects: “…malignant tumors…”
Get full text
Article -
822
Progress of research on prevention and treatment of radiation-induced rectal injury in patients with pelvic malignancy (盆腔恶性肿瘤放疗所致放射性直肠损伤的防治研究进展)
Published 2023-05-01Subjects: Get full text
Article -
823
-
824
-
825
Heterogeneity of Genetic Landscapes in Salivary Gland Tumors and Their Critical Roles in Current Management
Published 2022-06-01Subjects: Get full text
Article -
826
Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia
Published 2024-09-01Subjects: “…hematologic malignancies…”
Get full text
Article -
827
The significance of the immunohistochemical method in diagnosing atypical endometrial polyps as manifestations of localized hyperplasia
Published 2024-12-01Subjects: Get full text
Article -
828
A study of relationship between cardiac exposure dose-volume and cardiovascular autonomic dysfunction in radiotherapy
Published 2024-11-01Subjects: “…|thoracic radiotherapy|malignant tumor|cardiac autonomic function|heart rate variability|heart injuries…”
Get full text
Article -
829
-
830
NF-κB signaling and the tumor microenvironment in osteosarcoma: implications for immune evasion and therapeutic resistance
Published 2025-01-01Subjects: Get full text
Article -
831
The Effects of High Particulate Matter Levels on Platelet Recovery in Patients Receiving Prophylactic Platelet Transfusion
Published 2025-02-01Subjects: Get full text
Article -
832
Synthesis and Anti-Cancer Activity In Vitro of Synephrine Derivatives
Published 2024-12-01Subjects: Get full text
Article -
833
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary origin
Published 2025-01-01“…Abstract Background People with malignancy of undefined primary origin (MUO) have a poor prognosis and may undergo a protracted diagnostic workup causing patient distress and high cancer related costs. …”
Get full text
Article -
834
One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic
Published 2024-12-01“…Materials and Methods We have vaccinated 292 patients with all hematological malignancies with a third dose of mRNA COMIRNATY vaccine with a 12‐month follow‐up period in our center in Ostrava, Czech Republic. …”
Get full text
Article -
835
Mir-483-5p-mediated activating of IGF2/H19 enhancer up-regulates IGF2/H19 expression via chromatin loops to promote the malignant progression of hepatocellular carcinoma
Published 2025-01-01“…Finally, the effect of MED1 on the expression of IGF2/H19 as well as the malignant phenotype of HCC cells in vitro and in vivo mediated by miR-483-5p was evaluated. …”
Get full text
Article -
836
Overlapping of Serotonin Syndrome with Neuroleptic Malignant Syndrome due to Linezolid-Fluoxetine and Olanzapine-Metoclopramide Interactions: A Case Report of Two Serious Adverse Drug Effects Caused by Medication Reconciliation Failure on Hospital Admission
Published 2016-01-01“…The concomitant use of antipsychotic and/or antidepressant with drugs that may interact can lead to rare, life-threatening conditions such as serotonin syndrome and neuroleptic malignant syndrome. We describe a patient who has a history of taking two offending drugs that interact with drugs given during the course of hospital treatment which leads to the development of serotonin syndrome overlapped with neuroleptic malignant syndrome. …”
Get full text
Article -
837
Endoscopic ultrasound-guided hepaticogastrostomy and endoscopic retrograde cholangiopancreatography-guided biliary drainage for distal malignant biliary obstruction due to pancreatic cancer with asymptomatic duodenal invasion: a retrospective, single-center study in Japan
Published 2025-01-01Subjects: Get full text
Article -
838
CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
Published 2023-08-01“…Background Despite significant progress in the development of T cell-engaging therapies for various B-cell malignancies, a high medical need remains for the refractory disease setting, often characterized by suboptimal target levels.Methods To address this issue, we have developed a 65-kDa multispecific antibody construct, CLN-978, with affinities tuned to optimize the killing of low-CD19 expressing tumor cells. …”
Get full text
Article -
839
Adaptive Evolution Coupled with Retrotransposon Exaptation Allowed for the Generation of a Human-Protein-Specific Coding Gene That Promotes Cancer Cell Proliferation and Metastasis in Both Haematological Malignancies and Solid Tumours: The Extraordinary Case of MYEOV Gene
Published 2015-01-01“…This study focuses on MYEOV, an oncogene encoding for two protein isoforms, reported as causally involved in promoting cancer cell proliferation and metastasis in both haematological malignancies and solid tumours. First we document, via stringent in silico analysis, that MYEOV arose de novo in Catarrhini. …”
Get full text
Article -
840
The effectiveness of exercise-based interventions on muscle mass, muscle strength, functional performance, aerobic capacity, and health-related quality of life in adults with malignant lymphoma undergoing chemotherapy: a systematic review of randomized controlled trials
Published 2025-01-01“…Purpose: This study aims to identify and summarize evidence on the effectiveness of exercise-based interventions on muscle mass, muscle strength, functional performance, aerobic capacity, health-related quality of life (HRQoL), feasibility of the interventions, in patients with malignant lymphoma undergoing chemotherapy. Methods: A systematic search was conducted in six electronic databases and trials registers on November 15, 2023. …”
Get full text
Article